| Year |
Citation |
Score |
| 2017 |
Ramamurthy VP, Ramalingam S, Kwegyir-Afful AK, Hussain A, Njar VC. Targeting of protein translation as a new treatment paradigm for prostate cancer. Current Opinion in Oncology. PMID 28282343 DOI: 10.1097/Cco.0000000000000367 |
0.391 |
|
| 2016 |
Kwegyir-Afful AK, Murigi FN, Purushottamachar P, Ramamurthy VP, Martin MS, Njar VC. Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice. Oncotarget. PMID 28030797 DOI: 10.18632/oncotarget.14154 |
0.392 |
|
| 2016 |
Kwegyir-Afful AK, Bruno RD, Purushottamachar P, Murigi FN, Njar VC. Galeterone and VNPT55 disrupts Mnk-eIF4E to inhibit prostate cancer cell migration and invasion. The Febs Journal. PMID 27618366 DOI: 10.1111/Febs.13895 |
0.782 |
|
| 2016 |
Senthilmurugan R, Ramamurthy VP, Njar VC. Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets. The Journal of Steroid Biochemistry and Molecular Biology. PMID 27481707 DOI: 10.1016/j.jsbmb.2016.07.006 |
0.432 |
|
| 2016 |
Purushottamachar P, Kwegyir-Afful AK, Martin MS, Ramamurthy VP, Ramalingam S, Njar VC. Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate. Acs Medicinal Chemistry Letters. 7: 708-13. PMID 27437082 DOI: 10.1021/acsmedchemlett.6b00137 |
0.458 |
|
| 2016 |
Dransfield DT, Jacoby DB, Namdev N, Kwegyir-Afful A, Njar V. Galeterone to target proteasomal degradation of the androgen receptor in prostate tumor cells: A novel mechanism of action for treatment of AR-V7+ CRPC. Journal of Clinical Oncology. 34: e14092-e14092. DOI: 10.1200/Jco.2016.34.15_Suppl.E14092 |
0.457 |
|
| 2016 |
Njar V, Zoubeidi A, Corey E, Mostaghel E, Kwegyir-Afful A, Ramalingam S, Jacoby D. PD32-07 GALETERONE SHOWS ANTI-TUMOR ACTIVITY IN MULTIPLE PRE-CLINICAL MODELS THAT EXPRESS ANDROGEN RECEPTOR SPLICE VARIANTS, SUPPORTING CORRELATIVE PATIENT DATA SEEN IN ARMOR2 Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.683 |
0.307 |
|
| 2015 |
Kwegyir-Afful AK, Ramalingam S, Purushottamachar P, Ramamurthy VP, Njar VC. Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo. Oncotarget. 6: 27440-60. PMID 26196320 DOI: 10.18632/oncotarget.4578 |
0.428 |
|
| 2015 |
Liao Z, Gu L, Vergalli J, Mariani SA, De Dominici M, Lokareddy RK, Dagvadorj A, Purushottamachar P, McCue PA, Trabulsi E, Lallas CD, Gupta S, Ellsworth E, Blackmon S, Ertel A, ... ... Njar V, et al. Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia. Molecular Cancer Therapeutics. PMID 26026053 DOI: 10.1158/1535-7163.Mct-14-0883 |
0.53 |
|
| 2015 |
Mbatia HW, Ramalingam S, Ramamurthy VP, Martin MS, Kwegyir-Afful AK, Njar VC. Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenografts in mice. Journal of Medicinal Chemistry. 58: 1900-14. PMID 25634130 DOI: 10.1021/Jm501792C |
0.528 |
|
| 2015 |
Ramamurthy VP, Ramalingam S, Gediya L, Kwegyir-Afful AK, Njar VC. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines. Oncotarget. 6: 3195-210. PMID 25605250 DOI: 10.18632/oncotarget.3084 |
0.479 |
|
| 2015 |
Njar VC, Brodie AM. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. Journal of Medicinal Chemistry. 58: 2077-87. PMID 25591066 DOI: 10.1021/jm501239f |
0.424 |
|
| 2015 |
Jacoby DB, Zoubeidi A, Corey EB, Mostaghel E, Kwegyir-Afful AK, Ramalingam S, Njar V. Abstract B173: Galeterone shows anti-tumor activity in multiple pre-clinical models that express androgen receptor splice variants, supporting correlative patient data seen in ARMOR2 Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B173 |
0.512 |
|
| 2014 |
Godbole AM, Ramalingam S, Ramamurthy VP, Khandelwal A, Bruno RD, Upreti VV, Gediya LK, Purushottamachar P, Mbatia HW, Addya S, Ambulos N, Njar VC. VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague Dawley rats. European Journal of Pharmacology. 734: 98-104. PMID 24726842 DOI: 10.1016/J.Ejphar.2014.04.004 |
0.753 |
|
| 2014 |
Ramalingam S, Gediya L, Kwegyir-Afful AK, Ramamurthy VP, Purushottamachar P, Mbatia H, Njar VC. First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines. Oncotarget. 5: 530-43. PMID 24504069 DOI: 10.18632/Oncotarget.1528 |
0.422 |
|
| 2014 |
Ramalingam S, Gediya L, Purushottamachar P, Kwegyir-Afful A, Ramamurthy Vp, Mbatia H, Njar V. Abstract 756: First MNK degrading agents block phosphorylation of eIF4E, induce apoptosis, and inhibit cell growth, migration and invasion in triple-negative and HER2-overexpressing breast cancer cell lines Cancer Research. 74: 756-756. DOI: 10.1158/1538-7445.Am2014-756 |
0.528 |
|
| 2014 |
Taplin M, Chi K, Chu F, Cochran J, Edenfield W, Antonarakis E, Emmenegger U, Heath E, Hussain A, Njar V, Koletsky A, Lipsitz D, Nordquist L, Pili R, Rettig M, et al. 4 Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2 European Journal of Cancer. 50: 8. DOI: 10.1016/S0959-8049(14)70130-3 |
0.369 |
|
| 2013 |
Purushottamachar P, Godbole AM, Gediya LK, Martin MS, Vasaitis TS, Kwegyir-Afful AK, Ramalingam S, Ates-Alagoz Z, Njar VC. Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. Journal of Medicinal Chemistry. 56: 4880-98. PMID 23713567 DOI: 10.1021/Jm400048V |
0.803 |
|
| 2013 |
Tran K, Risingsong R, Royce DB, Williams CR, Sporn MB, Pioli PA, Gediya LK, Njar VC, Liby KT. The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. Carcinogenesis. 34: 199-210. PMID 23042302 DOI: 10.1093/Carcin/Bgs319 |
0.415 |
|
| 2012 |
Godbole AM, Purushottamachar P, Martin MS, Njar VC. Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1. Cancer Chemotherapy and Pharmacology. 70: 339-44. PMID 22580781 DOI: 10.1007/S00280-012-1877-Z |
0.811 |
|
| 2012 |
Godbole AM, Purushottamachar P, Martin MS, Daskalakis C, Njar VC. Autophagy inhibition synergistically enhances anticancer efficacy of RAMBA, VN/12-1 in SKBR-3 cells, and tumor xenografts. Molecular Cancer Therapeutics. 11: 898-908. PMID 22334589 DOI: 10.1158/1535-7163.Mct-11-0860 |
0.803 |
|
| 2012 |
Purushottamachar P, Patel JB, Gediya LK, Clement OO, Njar VC. First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds. European Journal of Medicinal Chemistry. 47: 412-23. PMID 22130607 DOI: 10.1016/J.Ejmech.2011.11.010 |
0.556 |
|
| 2012 |
Goss PE, Qi S, Hu H, Gediya LK, Purushottamachar P, Godbole AM, Njar VC. Anti-tumor effects of a novel retinoic acid metabolism blocking agent VN/14-1 in the N-methyl-N-nitrosourea-induced rat mammary carcinoma model and its effects on the uterus. Breast Cancer Research and Treatment. 133: 137-44. PMID 21842418 DOI: 10.1007/S10549-011-1724-7 |
0.761 |
|
| 2011 |
Godbole AM, Njar VC. New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer. Prostate Cancer. 2011: 918707. PMID 22111003 DOI: 10.1155/2011/918707 |
0.807 |
|
| 2011 |
Bruno RD, Vasaitis TS, Gediya LK, Purushottamachar P, Godbole AM, Ates-Alagoz Z, Brodie AM, Njar VC. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model. Steroids. 76: 1268-79. PMID 21729712 DOI: 10.1016/J.Steroids.2011.06.002 |
0.812 |
|
| 2011 |
Vasaitis TS, Bruno RD, Njar VC. CYP17 inhibitors for prostate cancer therapy. The Journal of Steroid Biochemistry and Molecular Biology. 125: 23-31. PMID 21092758 DOI: 10.1016/J.Jsbmb.2010.11.005 |
0.77 |
|
| 2010 |
Vasaitis TS, Njar VC. Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments. Future Medicinal Chemistry. 2: 667-80. PMID 21426013 DOI: 10.4155/Fmc.10.14 |
0.468 |
|
| 2010 |
Schayowitz A, Sabnis G, Goloubeva O, Njar VC, Brodie AM. Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR. British Journal of Cancer. 103: 1001-7. PMID 20842117 DOI: 10.1038/sj.bjc.6605882 |
0.442 |
|
| 2010 |
Swanson HI, Njar VC, Yu Z, Castro DJ, Gonzalez FJ, Williams DE, Huang Y, Kong AN, Doloff JC, Ma J, Waxman DJ, Scott EE. Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 38: 539-44. PMID 20233842 DOI: 10.1124/Dmd.109.031351 |
0.352 |
|
| 2009 |
Dexheimer TS, Gediya LK, Stephen AG, Weidlich I, Antony S, Marchand C, Interthal H, Nicklaus M, Fisher RJ, Njar VC, Pommier Y. 4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors. Journal of Medicinal Chemistry. 52: 7122-31. PMID 19883083 DOI: 10.1021/Jm901061S |
0.379 |
|
| 2009 |
Brodie A, Njar V, Macedo LF, Vasaitis TS, Sabnis G. The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer. Urologic Oncology. 27: 53-63. PMID 19111799 DOI: 10.1016/J.Urolonc.2008.07.036 |
0.535 |
|
| 2008 |
Bruno RD, Gover TD, Burger AM, Brodie AM, Njar VC. 17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Molecular Cancer Therapeutics. 7: 2828-36. PMID 18790763 DOI: 10.1158/1535-7163.Mct-08-0336 |
0.768 |
|
| 2008 |
Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang HB, Njar VC, Brodie AM. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Molecular Cancer Therapeutics. 7: 2348-57. PMID 18723482 DOI: 10.1158/1535-7163.MCT-08-0230 |
0.805 |
|
| 2008 |
Moreira VM, Vasaitis TS, Guo Z, Njar VC, Salvador JA. Synthesis of novel C17 steroidal carbamates. Studies on CYP17 action, androgen receptor binding and function, and prostate cancer cell growth. Steroids. 73: 1217-27. PMID 18582482 DOI: 10.1016/J.Steroids.2008.05.010 |
0.344 |
|
| 2008 |
Gediya LK, Khandelwal A, Patel J, Belosay A, Sabnis G, Mehta J, Purushottamachar P, Njar VC. Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro. Journal of Medicinal Chemistry. 51: 3895-904. PMID 18543902 DOI: 10.1021/Jm8001839 |
0.81 |
|
| 2008 |
Khandelwal A, Gediya L, Njar V. MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours. British Journal of Cancer. 98: 1234-43. PMID 18349838 DOI: 10.1038/Sj.Bjc.6604295 |
0.794 |
|
| 2008 |
Purushottamachar P, Khandelwal A, Vasaitis TS, Bruno RD, Gediya LK, Njar VC. Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent. Bioorganic & Medicinal Chemistry. 16: 3519-29. PMID 18316193 DOI: 10.1016/J.Bmc.2008.02.031 |
0.815 |
|
| 2008 |
Schayowitz A, Sabnis G, Njar VC, Brodie AM. Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Molecular Cancer Therapeutics. 7: 121-32. PMID 18202015 DOI: 10.1158/1535-7163.Mct-07-0581 |
0.471 |
|
| 2008 |
Gediya LK, Belosay A, Khandelwal A, Purushottamachar P, Njar VC. Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Bioorganic & Medicinal Chemistry. 16: 3352-60. PMID 18166465 DOI: 10.1016/J.Bmc.2007.12.007 |
0.804 |
|
| 2007 |
Moreira VM, Vasaitis TS, Njar VC, Salvador JA. Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors. Steroids. 72: 939-48. PMID 17884122 DOI: 10.1016/J.Steroids.2007.08.004 |
0.409 |
|
| 2007 |
Bruno RD, Njar VC. Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorganic & Medicinal Chemistry. 15: 5047-60. PMID 17544277 DOI: 10.1016/J.Bmc.2007.05.046 |
0.772 |
|
| 2007 |
Patel JB, Mehta J, Belosay A, Sabnis G, Khandelwal A, Brodie AM, Soprano DR, Njar VC. Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. British Journal of Cancer. 96: 1204-15. PMID 17387344 DOI: 10.1038/Sj.Bjc.6603705 |
0.816 |
|
| 2007 |
Purushottamachar P, Khandelwal A, Chopra P, Maheshwari N, Gediya LK, Vasaitis TS, Bruno RD, Clement OO, Njar VC. First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents. Bioorganic & Medicinal Chemistry. 15: 3413-21. PMID 17383188 DOI: 10.1016/J.Bmc.2007.03.019 |
0.807 |
|
| 2007 |
Patel JB, Khandelwal A, Chopra P, Handratta VD, Njar VC. Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents. Cancer Chemotherapy and Pharmacology. 60: 899-905. PMID 17345084 DOI: 10.1007/S00280-007-0438-3 |
0.835 |
|
| 2006 |
Belosay A, Brodie AM, Njar VC. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells. Cancer Research. 66: 11485-93. PMID 17145897 DOI: 10.1158/0008-5472.CAN-06-2168 |
0.399 |
|
| 2006 |
Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J, Handratta VD, Njar VC, Brodie AM, Yu LR, Veenstra TD, Chen H, et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell. 10: 309-19. PMID 17045208 DOI: 10.1016/J.Ccr.2006.08.021 |
0.334 |
|
| 2006 |
Njar VC, Gediya L, Purushottamachar P, Chopra P, Belosay A, Patel JB. Retinoids in clinical use. Medicinal Chemistry (ShāRiqah (United Arab Emirates)). 2: 431-8. PMID 16848757 DOI: 10.2174/157340606777724022 |
0.51 |
|
| 2006 |
Njar VC, Gediya L, Purushottamachar P, Chopra P, Vasaitis TS, Khandelwal A, Mehta J, Huynh C, Belosay A, Patel J. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorganic & Medicinal Chemistry. 14: 4323-40. PMID 16530416 DOI: 10.1016/J.Bmc.2006.02.041 |
0.794 |
|
| 2006 |
Huynh CK, Brodie AM, Njar VC. Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice. British Journal of Cancer. 94: 513-23. PMID 16449997 DOI: 10.1038/sj.bjc.6602971 |
0.49 |
|
| 2005 |
Gediya LK, Chopra P, Purushottamachar P, Maheshwari N, Njar VC. A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. Journal of Medicinal Chemistry. 48: 5047-51. PMID 16033284 DOI: 10.1021/jm058214k |
0.476 |
|
| 2005 |
Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman D, Farquhar R, Guo Z, Qiu Y, Brodie AM. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. Journal of Medicinal Chemistry. 48: 2972-84. PMID 15828836 DOI: 10.1021/Jm040202W |
0.454 |
|
| 2004 |
Patel JB, Huynh CK, Handratta VD, Gediya LK, Brodie AM, Goloubeva OG, Clement OO, Nanne IP, Soprano DR, Njar VC. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice. Journal of Medicinal Chemistry. 47: 6716-29. PMID 15615521 DOI: 10.1021/Jm0401457 |
0.696 |
|
| 2004 |
Handratta VD, Jelovac D, Long BJ, Kataria R, Nnane IP, Njar VC, Brodie AM. Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model. The Journal of Steroid Biochemistry and Molecular Biology. 92: 155-65. PMID 15555909 DOI: 10.1016/j.jsbmb.2004.07.006 |
0.392 |
|
| 2004 |
Wu C, Njar V, Brodie A, Borenstein M, Nnane I. Quantification of a novel retinoic acid metabolism inhibitor, 4-(1H-imidazol-1-yl)retinoic acid (VN/14-1RA) and other retinoids in rat plasma by liquid chromatography with diode-array detection. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 810: 203-8. PMID 15380716 DOI: 10.1016/J.Jchromb.2004.07.028 |
0.347 |
|
| 2003 |
Corbin CJ, Moran FM, Vidal JD, Ford JJ, Wise T, Mapes SM, Njar VC, Brodie AM, Conley AJ. Biochemical assessment of limits to estrogen synthesis in porcine follicles. Biology of Reproduction. 69: 390-7. PMID 12672661 DOI: 10.1095/Biolreprod.103.015578 |
0.302 |
|
| 2003 |
Njar VC. Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy. Mini Reviews in Medicinal Chemistry. 2: 261-9. PMID 12370067 DOI: 10.2174/1389557023406223 |
0.361 |
|
| 2002 |
Moran FM, Ford JJ, Corbin CJ, Mapes SM, Njar VC, Brodie AM, Conley AJ. Regulation of microsomal P450, redox partner proteins, and steroidogenesis in the developing testes of the neonatal pig. Endocrinology. 143: 3361-9. PMID 12193548 DOI: 10.1210/En.2002-220329 |
0.304 |
|
| 2001 |
Grigoryev DN, Long BJ, Njar VC, Brodie AH. Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor. The Journal of Steroid Biochemistry and Molecular Biology. 75: 1-10. PMID 11179903 DOI: 10.1016/S0960-0760(00)00131-X |
0.344 |
|
| 2000 |
Brodie AM, Njar VC. Aromatase inhibitors and their application in breast cancer treatment*. Steroids. 65: 171-9. PMID 10713305 DOI: 10.1016/S0039-128X(99)00104-X |
0.385 |
|
| 2000 |
Nnane IP, Njar VC, Liu Y, Lu Q, Brodie AM. Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo. The Journal of Steroid Biochemistry and Molecular Biology. 71: 145-52. PMID 10659703 DOI: 10.1016/S0960-0760(99)00129-6 |
0.406 |
|
| 1999 |
Grigoryev DN, Long BJ, Nnane IP, Njar VC, Liu Y, Brodie AM. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo. British Journal of Cancer. 81: 622-30. PMID 10574247 DOI: 10.1038/sj.bjc.6690739 |
0.506 |
|
| 1999 |
Njar VC, Brodie AM. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. Drugs. 58: 233-55. PMID 10473018 DOI: 10.2165/00003495-199958020-00003 |
0.39 |
|
| 1998 |
Brodie AM, Njar VC. Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications. The Journal of Steroid Biochemistry and Molecular Biology. 66: 1-10. PMID 9712406 DOI: 10.1016/S0960-0760(98)00022-3 |
0.344 |
|
| 1998 |
Njar VC, Kato K, Nnane IP, Grigoryev DN, Long BJ, Brodie AM. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer. Journal of Medicinal Chemistry. 41: 902-12. PMID 9526564 DOI: 10.1021/JM970568R |
0.377 |
|
| Show low-probability matches. |